One of many great things about #TexasLung24 , running into a stage 4 pt you hadn’t seen since moving from Texas yrs ago! What a gift. (posted w permission). #medicineisthebestjob TLC Conference

ALK+ NSCLC best practices from Vincent Lam With 4 highly active TKIs available, we are moving toward ⬆️ precision 🎯to choose b/t them 1L and select for treatment intensification. Will we soon consider variants? 🧬 TLC Conference #TexasLung24 ALK Positive Johns Hopkins Thoracic Oncology

Vaccine trial for ALK positive lung cancer opening soon ⁦Johns Hopkins Thoracic Oncology⁩ ⁦Vincent Lam⁩ #lcsm ⁦ALK Positive⁩ ⁦ALK Cancer Research⁩

Another important call to action as we raise awareness about lung cancer during #LCAM . Current prior auth/peer review system harms patients and contributes to clinician burnout. We must fix this. ama-assn.org/practice-manag…

We need to #FixPriorAuth ! It is harming patients & the doctor-patient relationship & fueling #PhysicianBurnout . #OncTwitter #MedTwitter

#Targets23 Dr. JessicaJLinMD with the latest update on repotrectinib in #ROS1 NSCLC. RR 79% with median duration of response of 34.1 months! mPFS 35.7m, mOS not reached. Strong CNS efficacy. New best in class for ROS1?

Exciting data from Leyuan Ma and Darrell Irvine team that vaccine-boosted CAR-T may improve durability of CAR-T for solid tumors, where antigen heterogeneity is a major barrier. Ongoing BNT211 CLDN6 CAR-T trial will hopefully show similar antigen spreading